Education
About Us
Working with TipRanks
Follow Us
Innoviva Inc (INVA)
NASDAQ:INVA
INVA Stock Chart & Stats
$19.77
-$0.05(-0.29%)
At close: 4:00 PM EST
$19.77
-$0.05(-0.29%)
Day’s Range― - ―
52-Week Range$16.52 - $22.76
Previous CloseN/A
Volume64.08K
Average Volume (3M)937.84K
Market Cap
$1.48B
Enterprise Value$1.28B
Total Cash (Recent Filing)$533.10M
Total Debt (Recent Filing)$323.23M
Price to Earnings (P/E)14.2
Beta0.18
Next Earnings
Mar 04, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.08
Shares Outstanding74,769,060
10 Day Avg. Volume1,262,492
30 Day Avg. Volume937,839
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)1.57
Price to Sales (P/S)3.03
P/FCF Ratio5.78
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit3.80
Enterprise Value/Ebitda6.36
Forecast
1Y Price Target
$32.25Price Target Upside63.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)1.79
Revenue Forecast (FY)$398.21M
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThe FDA has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea.
Financial PerformanceInnoviva's financial results revealed solid operational execution and royalty-based revenue resilience, with multiple revenue streams exceeding expectations.
Market ExclusivityZoliflodacin has been granted a Qualified Infectious Disease Product (QIDP) designation by the FDA, allowing it to benefit from extended market exclusivity.
Bears Say
Competitive ApprovalGepotidacin, a rival antibiotic agent aimed at the gonorrhea market, was likewise approved by the FDA and is slated to be launched by GlaxoSmithKline plc.
Future Growth ExpectationsThe bar for performance needed from the IST platform is now raised, indicating higher expectations for future growth.
Royalty Patent CliffThe company's 2031 royalty-related patent cliff is anticipated to start weighing on stock performance, reflecting historical trends in the pharma sector.
Innoviva News
INVA FAQ
What was Innoviva Inc’s price range in the past 12 months?
Innoviva Inc lowest stock price was $16.52 and its highest was $22.76 in the past 12 months.
What is Innoviva Inc’s market cap?
Innoviva Inc’s market cap is $1.48B.
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is Mar 04, 2026 which is in 67 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on Nov 05, 2025. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.62.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is 0.6.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 74,769,060 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of $1.08 in its last earnings report, beating expectations of $0.46. Following the earnings report the stock price went up 12.891%.
Which hedge fund is a major shareholder of Innoviva Inc?
Currently, no hedge funds are holding shares in INVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.25 (63.13% Upside)
$32.25 (63.13% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 312.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.19%
12-Months-Change
Fundamentals
Return on Equity
15.17%
Trailing 12-Months
Asset Growth
16.04%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Stock 12 Month Forecast
Average Price Target
$32.25
▲(63.13% Upside)
Technical Analysis
Ownership Overview
8.51% Insiders
21.80% Mutual Funds
13.54% Other Institutional Investors
27.79% Public Companies and
Individual Investors